Swiss Researchers Pioneer Breakthrough in Lymphoma Treatment

Paul Scherrer Institute develops promising new cancer therapy using terbium-161, showing significantly improved effectiveness compared to existing treatments.

Key Takeaways

AI

Paul Scherrer Institute (PSI) researchers have developed a new lymphoma therapy using terbium-161.
Terbium-161 killed cancer cells 2 to 43 times more effectively than lutetium-177 in laboratory experiments.
Mice treated with terbium-161 survived twice as long on average compared to those treated with lutetium-177.
The radioactive substance is coupled to an antibody that targets the CD30 receptor on tumour cells.
Approximately one-third of all lymphoma patients exhibit the CD30 receptor on their tumour cells.

By The Numbers

43x

increase in cell-killing effectiveness

2x

survival duration

1/3

patient applicability

They Said

"Our results provide good indications that the active substance could also prove to be an effective agent against lymphomas in humans."
— Elisa Rioja-Blanco

"Terbium-161 fires more precise projectiles."
— Researchers

1

Swiss Science Shatters Expectations

2

The Precision Guided Mechanism

3

Outperforming the Global Standard

4

A New Era for Human Trials

Sources & References

Swiss researchers develop new treatment against lymphoma

SWI swissinfo.ch